|
|
- 2017
维生素D对活动期系统性红斑狼疮患者内皮祖细胞的影响
|
Abstract:
摘要 目的:观察活动期系统性红斑狼疮(SLE)患者内皮祖细胞(EPCs)数量及功能的变化,并探讨维生素D对SLE患者EPCs数量及功能的影响.方法: 收集30例SLEDAI评分大于8分,病情均处于活动期的SLE患者,30例年龄与性别匹配的健康人作为正常对照;酶联免疫吸附试验(ELISA)检测外周血25羟基维生素D [25(OH)D]水平;密度梯度离心和贴壁培养法分离培养EPCs,流式细胞术检测CD34+/VEGFR-2+ EPCs 在全血中的比例;通过计数再贴壁和构建侵袭小室检测EPCs黏附和迁移能力.结果:①体外培养过程中,活动期SLE患者EPCs数量(0.028±0.017)%显著低于正常对照组 (0.067±0.012)%,有统计学差异(P<0.05);②活动期SLE患者EPCs迁移率(1.7±0.9)‰及黏附能力(19±7)显著低于正常对照组EPCs迁移率(3.1±1.6) ‰及黏附能力(34±11),有统计学差异(P<0.05);③活动期SLE患者外周血25(OH)D质量浓度(14.47±10.39)ng/mL水平低于健康对照组质量浓度(24.15±7.98)ng/mL,有统计学差异(P<0. 05);④25(OH)D能够增加活动期SLE患者EPCs数量(0.045±0.012)%,高于未加25(OH)D 组(0.031±0.012)%,有统计学差异(P<0.05);⑤25(OH)D能够增加活动期SLE患者EPCs迁移率(2.6±0.7)‰及黏附能力(24±9),高于未加25(OH)D组迁移率(1.3±0.8)‰及黏附能力(13±6),有统计学差异(P<0.05).结论:SLE患者维生素D水平降低,可诱发Ⅰ型干扰素通路活化,从而导致EPCs数量和/或功能异常,最终造成狼疮患者血管内皮损伤后修复障碍引发动脉粥样硬化.
| [1] | 梅奕洁, 吴 实, 林 琳, 等. 女性系统性红斑狼疮患者外周血Tim-1表达水平及其与疾病活动的相关性[J]. 暨南大学学报, 2016, 37(4): 324-326. |
| [2] | 张春燕, 吕良敬, 鲍春德, 等. 系统性红斑狼疮与早发动脉粥样硬化及其相关危险因素[J]. 中华风湿病学杂志, 2007, 11(8): 458-461. |
| [3] | ZHANG C Y, LV L J, BAO C D, et al. Premature atherosclerosis in systemic lupus erythematosus and its associated risk factors[J]. Chinese Journal of Rheumatology, 2007, 11(8): 458-461. |
| [4] | MOON J H, CHAE M K, KIM K J, et al. Decreased endothelial progenitor cells and increased serum glycated albumin are independently correlated with plaque-forming carotid artery atherosclerosis in type 2 diabetes patients without documented ischemic disease[J]. Circ J, 2012,76(9): 2273-2279. |
| [5] | LIM C S, KIRIAKIDIS S, SANDISON A, et al. Hypoxia-inducible factor pathway and diseases of the vascular wall[J]. J Vasc Surg, 2013, 58(1): 219-230. |
| [6] | WESTERWEEL P E, LUIJTEN R K, HOEFER I E, et al. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus crythematosus[J]. Ann Rheum Dis, 2007, 66(7): 865-870. |
| [7] | TELLES R W, LANNA C C, FERREIRA G A, et al. Carotid atherosclerotic alterations in systemic lupus erythematosus patients treated at a Brazilian university setting[J]. Lupus, 2008, 17(2): 105-113. |
| [8] | LERTRATANAKUL A, WU P, DYER A R, et al. Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus[J]. Arthritis Care & Research, 2014, 66(8): 1177-1185. |
| [9] | MEI Y J, WU S, LIN L, et al. The expression of T cell immunoglobulin domain and mucin domain-1 in the peripheral blood and its association with activity of female systemic lupus erythematosus[J]. Journal of Jinan University, 2016, 37(4): 324-326. |
| [10] | KISS E, SOLTESZ P, DER H, et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients[J]. Autoimmun, 2006, 27(4): 211-217. |
| [11] | LEE P Y, LI Y, RICHARDS H B, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus[J]. Arthritis Rheum, 2007, 56(11): 3759-3769. |
| [12] | DENNY M F, THACKER S, MEHTA H, et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis[J]. Blood, 2007, 110(8): 2907-2915. |
| [13] | ADLER B, ADLER H, JUNGI T W, et al. Interferon-alpha primes macrophages for lipopolysac-charide-induced apoptosis[J]. Biochem Biophys Res Commun, 1995, 215(3): 921-927. |
| [14] | LERMAN M, BURNHAM J, BEHRENS E. 1,25 dihydroxyvitamin D3 limits monocyte maturation in lupus sera[J]. Lupus, 2011, 20(7): 749-753. |
| [15] | TERRIER B, DERIAN N, SCHOINDRE Y, et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients throush vitamin D supplementation[J]. Arthritis Res Ther, 2012, 14(5): R221. |
| [16] | KAMEN D, ARANOW C. Vitamin D in systemic lupus erythematosus[J]. Curt Opin Rheumatol, 2008, 20(5): 532-537. |
| [17] | ADORINI L, PENNA G. Control of autoimmuine diseases by the vitamin D endocrine system[J]. Nat Clin Pract Rheumatol, 2008, 4(8): 404-412. |
| [18] | ROMAN M J, SHANKER B A, DAVIS A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus[J]. N Engl J Med, 2003, 349(25): 2399-2406. |
| [19] | ASANUMA Y, OESER A, SHINTANI A K et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus[J]. N Engl J Med, 2003, 349(25): 2407-2415. |
| [20] | CRAMPTON S P, MORAWSKI P A, BOLLAND S. Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus[J]. Dis Model Mech, 2014, 7(9): 1033-1046. |
| [21] | MCMAHON M, SKAGGS B J, GROSSMAN J M, et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus[J]. Arthritis & Rheumatology, 2014, 66(1): 130-139. |
| [22] | ASAHARA T, MUROHARA T, SULLIVAN A, et al. Isolation of putative progenitor endothelial cells for angiogenesis[J]. Science, 1997, 275(5302): 964-967. |
| [23] | ABOU-SALEH H, YACOUB D, THéORêT J F, et al. Endothelial progenitor cells bind and inhibit platelet function and thrombus formation[J]. Circulation, 2009,120(22): 2230-2239. |
| [24] | ESDAILE J M, ABRAHAMOWICZ M, GRODZICKY T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus[J]. Arthritis Rheum, 2001, 44(10): 2331-2337. |
| [25] | RAJAGOPALAN S, SOMERS E C, BROOK R D, et al. Endothelial cell apotosis in systemic lupus erythematosus:a common pathway for abnormal vascular function and thrombosis propensity[J]. Blood, 2004, 103(10): 3677-3683. |
| [26] | EL-MAGADMI M, BODILL H, AHMAD Y, et al. Systemic lupus erythematosus:an independent risk factor for endothelial dysfunction in women[J]. Circulation, 2004, 110(4): 399-404. |
| [27] | CEDERHOLM A, SVENUNGSSON E, JENSEN-URSTAD K, et al. Decreased binding of annexin v to endothelial cells: a potential mechanism in atherosthrombosis of patients with systemic lupus erythematosus[J]. Arterioscler Thromb Vasc Biol, 2005, 25(1): 198-203. |
| [28] | LINKER-ISRAELI M, ELSTNER E, KLINENBERG J R, et al. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoslobulin production by SLE-derived PBMC[J]. Clin Immunol, 2001, 99(1): 82-93. |
| [29] | MANDAL M, TRIPATHY R, PANDA A K, et al. Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha[J]. Arthritis Research & Therapy, 2014, 16(1): R49. |
| [30] | KAMEN D, ARANOW C. Vitamin D in systemic lupus erythematosus[J]. Curt Opin Rheumatol, 2008, 20(5): 532-537. |
| [31] | MARTINS D, TAREEN N, ARTAZA J, et al. The effect of short term vitamin D supplementation on the inflammatory and oxidative mediators of arterial stiffness[J]. Health, 2014, 6(12): 1503-1511. |
| [32] | LERTRATANAKUL A, WU P, DYER A, et al. 25-Hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: Data from a large international inception cohort[J]. Arthritis Care & Research, 2014, 66(8): 1167-1176. |
| [33] | ROBINSON A B, TANGPRICHA V, GURION R, et al. Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus:an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy[J]. Lupus Science & Medicine, 2014, 1(1): e000011. |
